Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
The purpose of this research is to understand how to apply cardiac magnetic resonance imaging (CMR) to women with small artery heart disease by looking at the CMRs of women without heart disease. The investigators will study 40 women with no heart disease to learn more about the usefulness of CMR.
Women suffer more than men from this disorder of the small vessels compared to the large vessels. This results in delays in diagnosis, missed opportunities for treatment, and likely contributes to the increased death rate from heart disease in women compared to men. Current testing for small vessel disease is invasive and not performed routinely and women are often not initiated on appropriate lifesaving treatment. New imaging and noninvasive technology exists that may improve this situation. Imaging techniques such as cardiac magnetic resonance imaging (CMR) can now show the inner layers of the heart where the small vessel abnormality and myocardial ischemia exist. These techniques, while promising, have not been tested to determine if they can be used to diagnose and treat the small vessel coronary heart disease condition. They also have not been studied extensively in women without heart disease.
Gadolinium, the contrast agent that will be given Intravenously to all study participants during the cardiac MRI procedure, is contraindicated to patients with renal impairment. Even though it will only be given once to each of our patients, the investigators still wanted to establish the fact that these study participants have "normal" or good renal functioning by doing BUN and Creatinine blood tests prior to the administration of this contrast agent to their system. By adding these lab tests, the investigators will be more cautious to the well-being and safety of the study participants.
The investigators will be recruiting women aged 35-65 years with no known heart disease or heart disease risk factors like high blood pressure or high cholesterol. Participants will discuss the cardiac magnetic resonance procedure with a research doctor and if they agree, will fill out questionnaires related to their health, have blood draw and then undergo the CMR procedure. This can be completed in 1 or 2 visits. No follow up is needed.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing - Ancillary Study to Coronary Endothelial Function and Microvascular Disease in Women|
- Cardiac MRI [ Time Frame: at study visit ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
|Study Start Date:||May 2007|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
Other: Cardiac MRI
up to 3 CMRI scans per participant in 1-4 months
The women will be consented and enrolled. They will:
- fill out baseline demographic and health history questionnaires;
- have an exercise treadmill test (ETT) To rule out any underlying ischemic heart disease;
- undergo rest-stress CMR testing (up to 3 scans);
- peripheral arterial tonometry; and
- have blood drawn for hematocrit, blood urea nitrogen (BUN),creatinine, and research protein quantitation with mass spectrometry and enzyme-linked immunosorbent assay (ELISA) for sensitive quantitation of cardiovascular biomarkers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573339
|Contact: Rosardio Ando||310-423-9666||AndoR@cshs.org|
|Contact: Ying Mou, PhD||310-248-7669||Mouy@cshs.org|
|United States, California|
|Cedars-Sinai Women's Heart Center||Recruiting|
|Los Angeles, California, United States, 90048|
|Contact: Rosario Ando 310-423-9666 AndoR@cshs.org|
|Contact: Ying Mou, PhD 310-248-7669 MouY@cshs.org|
|Principal Investigator: C. Noel Bairey Merz, MD|
|Principal Investigator:||C. Noel Bairey Merz, MD||Cedars-Sinai Medical Center|